Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
9 min read
HN-2301 in Myasthenia Gravis: NCT06965309 Clinical Landscape Report 2026
18 September 2026
NCT06965309 clinical landscape for Myasthenia Gravis: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
CLY-124 in Hematologic Diseases: PACTR202505486265852 Clinical Landscape Report 2026
18 September 2026
PACTR202505486265852 clinical landscape for Hematologic Diseases: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Debamestrocel in Amyotrophic Lateral Sclerosis: NCT06973629 Clinical Landscape Report 2026
18 September 2026
NCT06973629 clinical landscape for Amyotrophic Lateral Sclerosis: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Universal allogeneic anti-CD19/BCMA CAR T-cells(Changzhou No.2 People's Hospital) in Myositis: NCT06978738 Clinical Landscape Report 2026
18 September 2026
NCT06978738 clinical landscape for Myositis: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Inebilizumab-cdon in Myasthenia Gravis: NCT06987539 Clinical Landscape Report 2026
18 September 2026
NCT06987539 clinical landscape for Myasthenia Gravis: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Anti-BAFFR CART(Tianjin Medical University General Hospital) in Idiopathic Inflammatory Myopathies: NCT07022197 Clinical Landscape Report 2026
18 September 2026
NCT07022197 clinical landscape for Idiopathic Inflammatory Myopathies: endpoints, sponsor, phase, geography, readouts, asset context and development white sp…
9 min read
nL-CHCHD-001 in Amyotrophic Lateral Sclerosis: NCT06977451 Clinical Landscape Report 2026
18 September 2026
NCT06977451 clinical landscape for Amyotrophic Lateral Sclerosis: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
MTP-101-C in Amyotrophic Lateral Sclerosis: NCT07017946 Clinical Landscape Report 2026
18 September 2026
NCT07017946 clinical landscape for Amyotrophic Lateral Sclerosis: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
M-102.4 in Neurodegenerative Diseases: ACTRN12625000511437 Clinical Landscape Report 2026
18 September 2026
ACTRN12625000511437 clinical landscape for Neurodegenerative Diseases: endpoints, sponsor, phase, geography, readouts, asset context and development white sp…
9 min read
Usnoflast in Amyotrophic Lateral Sclerosis: NCT07023835 Clinical Landscape Report 2026
18 September 2026
NCT07023835 clinical landscape for Amyotrophic Lateral Sclerosis: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Imeroprubart in Myasthenia Gravis: NCT07039916 Clinical Landscape Report 2026
18 September 2026
NCT07039916 clinical landscape for Myasthenia Gravis: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Digoxin in Amyotrophic Lateral Sclerosis: NCT07047209 Clinical Landscape Report 2026
18 September 2026
NCT07047209 clinical landscape for Amyotrophic Lateral Sclerosis: endpoints, sponsor, phase, geography, readouts, asset context and development white space.